Management of hyperkalaemia in the Italian clinical practice: impact of diverse potassium binders on outcomes and costs in patients with chronic kidney disease and heart failure
Introduction Hyperkalemia is a common and clinically relevant condition in patients with chronic kidney disease (CKD)
and heart failure (HF), often limiting optimal use of renin–angiotensin–aldosterone system inhibitors (RAASi).
Methods This real-world study evaluated adherence, clinical outcomes, and healthcare costs among Italian patients initiating
patiromer, sodium zirconium cyclosilicate (SZC), or sodium polystyrene sulfonate (SPS) between January 2022 and
June 2024.
Results Administrative data covering about 10% of the Italian population identified 1953 patients: 249 on patiromer, 387 on
SZC, and 1317 on SPS. After full matching, 67.5% of patiromer patients were adherent at 6 months, compared with 20.4%
for SZC and 0.5% for SPS (p < 0.001). Over the total follow-up, adherence remained higher with patiromer (42.5% vs 13.4%
and 0.5%). During the first 6 months, HF-related hospitalization rates were lower with patiromer versus SZC (5.4 vs 12.8
events per 100 person-years; p = 0.079), becoming significant over overall follow-up (5.3 vs 15.7; p = 0.003). Composite
HF outcomes at 6 months were also lower with patiromer compared with SZC (5.3 vs 17.4; p = 0.012) and SPS (3.4 vs 24.8;
p = 0.005). At 12 months, total healthcare costs were significantly lower with patiromer than with SZC and SPS (€5645 vs
€8500 and €4736 vs €6234; p < 0.001). Overall, patiromer use was associated with better adherence, fewer HF-related events,
and reduced healthcare expenditure.
Conclusions These findings suggest a patiromer potential role for sustained potassium binder therapy in supporting RAASi
optimization and improving clinical management in routine practice, but confirmation through direct comparative prospective
randomized trials is needed
The economic impact of multimorbidity in Italy:evaluation of direct costs and scenario analysis ofpatients with type 2 diabetes, heart failure, andchronic kidney disease using real-world data
ABSTRACTObjectives: This study aimed to evaluate the healthcare costs associated with managing type 2 diabetes (T2D),chronic kidney disease (CKD), and heart failure (HF) in Italy. Specifically, the research investigated the economicimpact on the Italian National Health System due to the increased clinical complexity and multimorbidity amongpatients with these conditions.Methods: A predictive model was developed to… Read More »The economic impact of multimorbidity in Italy:evaluation of direct costs and scenario analysis ofpatients with type 2 diabetes, heart failure, andchronic kidney disease using real-world data
RWE in oncologia: uso dei database per identificare isottotipi molecolari del cancro mammario metastatico in Italia
Introduction: The use of Real-World Evidence (RWE) is gaining increasing relevance in oncology, offering a complementaryperspective to randomised clinical trials (RCTs). In Italy, administrative databases represent a promisingsource to explore treatment patterns and distribution of molecular subtypes in metastatic breast cancer(mBC). This study was aimed at evaluating the feasibility and accuracy of using administrative data… Read More »RWE in oncologia: uso dei database per identificare isottotipi molecolari del cancro mammario metastatico in Italia
Healthcare Costs and Treatment Patterns of Triplet Therapies in Relapsed/Refractory Multiple Myeloma: Real World Evidence from Italy
Purpose: This analysis sought to characterize patients with relapsed or refractory multiple myeloma (RRMM) on triplet therapy with immunomodulatory agents/proteasome inhibitors/monoclonal antibodies combined with dexamethasone, describing their demographic and clinical features, therapeutic pathways and the related healthcare costs for the Italian National Health Service (NHS).Patients and Methods: A retrospective observational analysis was conducted on administrative… Read More »Healthcare Costs and Treatment Patterns of Triplet Therapies in Relapsed/Refractory Multiple Myeloma: Real World Evidence from Italy
Evoluzione dei trattamenti per l’angioedema ereditarioin Italia: utilizzo del lanadelumab nella pratica clinica
Introduction: Hereditary angioedema (HEA) is a rare genetic disorder characterised by recurrent episodes ofedema affecting various body districts. HEA therapy includes treatment of acute attacks and short- or long-termprophylaxis.Objective: To describe the main demographic and clinical characteristics of patients with HEA in real Italian clinicalpractice, as well as the use of pharmacological treatments, the use… Read More »Evoluzione dei trattamenti per l’angioedema ereditarioin Italia: utilizzo del lanadelumab nella pratica clinica
The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor therapy in Italian clinical practice
Aims Hyperkalemia (HK) is prevalent in patients with chronic kidney disease (CKD) and heart failure, particularly those on renin-angiotensin-aldosterone system inhibitors (RAASi). However, HK treatment often necessitates RAASi discontinuation. Sodium zirconium cyclosilicate (SZC), reimbursed in Italy since 2021, offers a new treatment option for HK. This study aimed to assess real-world SZC use and resulting… Read More »The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor therapy in Italian clinical practice
Real world evidence: patients with alopecia areata in Italy
BACKGROUN D: This real-world analysis aimed at characterizing patients hospitalized for alopecia areata (AA ) in Italy, focusing on comorbidities, treatment patterns and the economic burden for disease management.METHODS: Administrative databases of healthcare entities covering 8.9 million residents were retrospectively browsed to include patients of all ages with hospitalization discharge diagnosis for AA from 2010… Read More »Real world evidence: patients with alopecia areata in Italy
Analisi del percorso terapeutico e del consumo di risorse sanitarie in pazienti diabetici in trattamento insulinico: uno studio di real-world evidence su un campione di ASL della regione Sicilia
Italian reports indicate that more than one-third of patients with type 2 diabetes (T2D) require insulin therapy within 8 years of diagnosis, and commonly basal insulin represents the frontline option. An observational analysis was conducted with the aim of investigating patients treated with basal insulin alone in a sample of Local health Units of Sicily… Read More »Analisi del percorso terapeutico e del consumo di risorse sanitarie in pazienti diabetici in trattamento insulinico: uno studio di real-world evidence su un campione di ASL della regione Sicilia
Analisi real-world della epidemiologia e della gestione terapeutica dei pazienti affetti da fibrosi polmonare idiopatica in un contesto di pratica clinica italiana
La fibrosi polmonare idiopatica (IPF) è spesso diagnosticata tardivamente, con conseguente ritardo nell’inizio di terapie in grado di rallentare la progressione di malattia e il declino della funzione polmonare. Lo studio, condotto in un setting di reale pratica clinica italiana, ha valutato l’impatto dell’intervallo diagnostico di IPF sul burden clinico ed economico della patologia, focalizzandosi su epidemiologia, pattern terapeutico,… Read More »Analisi real-world della epidemiologia e della gestione terapeutica dei pazienti affetti da fibrosi polmonare idiopatica in un contesto di pratica clinica italiana
Characteristics and drug utilization of patients with hereditary angioedema in Italy, a real world-analysis
This real-world analysis investigated the characteristics and treatment patterns of patientswith hereditary angioedema (HAE) in Italy using the administrative data of health units across Italy.Patients were identified via exemption code or HAE-specific treatments (thus, all known forms, typeI, II and, III, were included). The index date was that of first prescription of HAE treatments withinthe… Read More »Characteristics and drug utilization of patients with hereditary angioedema in Italy, a real world-analysis